These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 18058474)

  • 1. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    O'Connor OA; Wright J; Moskowitz C; Muzzy J; MacGregor-Cortelli B; Stubblefield M; Straus D; Portlock C; Hamlin P; Choi E; Dumetrescu O; Esseltine D; Trehu E; Adams J; Schenkein D; Zelenetz AD
    J Clin Oncol; 2005 Feb; 23(4):676-84. PubMed ID: 15613699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
    J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
    O'Connor O; Wright J; Moskowitz CH; Muzzy J; MacGregor-Cortelli B; Hamlin P; Straus D; Trehu E; Schenkein DP; Zelenetz AD
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S21-2. PubMed ID: 19791425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of mantle cell lymphoma: targeting the microenvironment.
    Drach J; Seidl S; Kaufmann H
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib for the treatment of mantle cell lymphoma.
    Kane RC; Dagher R; Farrell A; Ko CW; Sridhara R; Justice R; Pazdur R
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5291-4. PubMed ID: 17875757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
    Jackson G; Einsele H; Moreau P; Miguel JS
    Cancer Treat Rev; 2005 Dec; 31(8):591-602. PubMed ID: 16298074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib in mantle cell lymphoma.
    Suh KS; Goy A
    Future Oncol; 2008 Apr; 4(2):149-68. PubMed ID: 18407730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
    Koprivnikar JL; Cheson BD
    Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.
    Fisher RI
    J Clin Oncol; 2005 Feb; 23(4):657-8. PubMed ID: 15613690
    [No Abstract]   [Full Text] [Related]  

  • 17. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
    Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
    J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
    O'Connor OA; Moskowitz C; Portlock C; Hamlin P; Straus D; Dumitrescu O; Sarasohn D; Gonen M; Butos J; Neylon E; Hamelers R; Mac-Gregor Cortelli B; Blumel S; Zelenetz AD; Gordon L; Wright JJ; Vose J; Cooper B; Winter J
    Br J Haematol; 2009 Apr; 145(1):34-9. PubMed ID: 19220284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Proteasome inhibitors].
    Hatake K; Mishima Y; Terui Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.